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Abstract 
 
It has been suggested that n-3 polyunsaturated fatty acids, such as 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), protect against 
cardiovascular diseases, and EPA/arachidonic acid (AA) and DHA/AA ratios in 
the serum has been focused on as risk markers for coronary artery disease 
(CAD). The purpose of this study was to clarify difference of the clinical 
significance between the EPA/AA ratio and DHA/AA ratio in patients with CAD. In 
369 consecutive patients with confirmed or suspected CAD who underwent 
diagnostic coronary angiography, we measured serum levels of EPA, DHA and 
AA, and calculated the EPA/AA and DHA/AA ratios. The EPA/AA ratio was 
significantly lower in acute coronary syndrome (ACS) patients than in patients 
with chronic CAD or chest pain syndrome (0.27±0.19 vs 0.44±0.20, respectively, 
P<0.01), whereas the DHA/AA ratio was similar in the two groups (0.78±0.27 vs 
0.79±0.37). Multiple logistic regression analysis for discrimination of ACS from 
other disease entities using various biomarkers related to coronary risk showed 
that the EPA/AA ratio (odds ratio: 0.0012, 95% confidence interval: 0.00-0.16, 
P<0.01), but not DHA/AA ratio (odds ratio: 1.05, 95% confidence interval: 
0.98-1.12), was a significant independent predictive factor. Our findings suggest 
that the EPA/AA ratio might be more closely associated with pathophysiology of 
CAD, especially with that of ACS, compared with the DHA/AA ratio.  
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INTRODUCTION 
 
It has long been noted that consumption of fish or fish oil may prevent 
cardiovascular events. Since the 1980s various epidemiological studies around the world 
have suggested that n-3 polyunsaturated fatty acids (PUFA), such as eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA), which are contained in fish oils, protect 
against the occurrence of cardiovascular events in comparison with n-6 PUFA as 
arachidonic acid (AA). Accordingly, supplemental intake of n-3 PUFA is 
recommended.1-3 The Japan Eicosapentaenoic acid Lipid Intervention Study (JELIS) 
showed that administration of high-purity EPA agents in addition to statins reduced the 
incidence of cardiovascular events.4 EPA and DHA differ in their biochemical effects 
and functions, and it is not clear which is more effective for preventing cardiovascular 
events. Also, the EPA/AA and DHA/AA ratios, which reflect the intake of n-3 PUFA 
relative to n-6 PUFA, have attracted attention as possible new cardiovascular risk 
markers. In addition to various conventional risk markers, 5 the EPA/AA and DHA/AA 
ratios also promise to predict future cardiovascular events. The purpose of the present 
study was to clarify the clinical significance of the EPA/AA and DHA/AA ratios in 
patients with coronary artery disease (CAD). 
 
 
METHODS 
 
Study design 
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We recruited 369 consecutive patients confirmed or suspected CAD (285 men, 84 
women, aged 66±11 yrs) who underwent diagnostic coronary angiography. Those 
patients who were diagnosed with ST elevation myocardial infarction, non-ST elevation 
myocardial infarction, and unstable angina were categorized as acute coronary 
syndrome (ACS). In patients who were without physical coronary artery stenosis an 
acetylcholine provocation test was performed. Patients in whom coronary artery spasm 
was provoked were diagnosed as having coronary spastic angina (CSA), and those in 
whom it was not provoked as having chest pain syndrome. Patients who had taken EPA 
or DHA as an agent or dietary supplement were excluded from the study. In these 369 
patients we measured the serum concentrations of EPA, DHA and AA in venous blood 
taken before the coronary angiography, and calculated the EPA/AA and DHA/AA ratios. 
As conventional biomarkers for coronary risk factors, the levels of serum creatinine, 
hemoglobin A1c, total cholesterol, low density lipoprotein (LDL)-cholesterol, high 
density lipoprotein (HDL)-cholesterol, triglycerides, and uric acid were also measured. 
Estimated glomerular filtration rate (eGFR) was calculated using the method described 
in the Japanese Society of Nephrology CKD Practice Guide.6 The study was approved 
by the ethics committee of Dokkyo Medical University, and informed consent was 
obtained from each patient.  
 
Measurement of serum fatty acids 
     Serum fatty acids were assayed by gas chromatography (SRL, Tokyo, Japan). 
Briefly, total lipids in plasma were extracted according to Folch, followed by hydrolysis 
to release free fatty acids. Free fatty acids were then esterified with potassium 
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methoxide/methanol and boron trifluoride/methanol. The methylated fatty acids were 
analyzed using a GC-17A gas chromatograph (Shimadzu Corporation, Kyoto, Japan) 
with an omegawax-250 capillary column (SUPELCO, Sigma-Aldrich Japan, Tokyo, 
Japan). Reproducibilities (i.e., coefficients of variation) of the determination of serum 
EPA, DHA, and AA by this method have been reported to be 4.4%, 2.3%, and 3.8%, 
respectively.7  
 
Statistical analysis 
Data were expressed as mean±standard deviation. The two groups were compared 
using Student’s unpaired t-test for continuous variables.  Multi-group comparisons 
were performed using one-way analysis of variance (ANOVA) followed by a post-hoc 
Fisher’s Least Significant Difference test. Multiple logistic regression analysis was 
performed for discrimination of ACS from chronic CAD, such as stable angina pectoris 
(SAP), old myocardial infarction (OMI), CSA, and chest pain syndrome, using various 
biomarkers of coronary risk. Statistical significance was defined as P<0.05. All 
statistical analyses were performed using statistical software (Excel To-kei 2012, SSRI 
Inc., Tokyo, Japan). 
 
 
RESULTS 
 
The clinical backgrounds of the patients are shown in Table 1. In all subjects lipid 
metabolism appeared to be well controlled on statin treatment. Serum creatinine, eGFR 
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and hemoglobin A1c were 0.86±0.30 mg/dl, 71±19 ml/min/1.73m2, and 6.3±1.2%, 
respectively.  
Both the EPA/AA ratio and DHA/AA ratio were lower in younger patients (<60 
yr) than in older patients (≥60 yr) (0.36±0.20 vs 0.47±0.30, respectively, P<0.0001, and 
0.72±0.28 vs 0.96±0.33, P<0.001). The EPA/AA ratio was lower in females than in 
males (0.36±0.25 vs 0.44±0.29, P<0.05), but a gender difference was not seen in the 
DHA/AA ratio (0.87±0.55 vs 0.91±0.37).  
In the disease entities of ACS, SAP, OMI, CSA and chest pain syndrome, the 
EPA/AA ratios were 0.35±0.13, 0.49±0.20, 0.47±0.20, 0.47±0.23, 0.42±0.19, 
respectively, and the DHA/AA ratios were 0.78±0.23, 0.95±0.37, 0.86±0.36, 0.95±0.32, 
0.95±0.36, respectively. The EPA/AA ratio was significantly lower in the ACS group 
than in each of the SAP (P<0.05), CSA (P<0.01) and chest pain syndrome (P<0.05) 
groups. The DHA/AA ratio in the ACS group was significantly lower than in the SAP 
group (P<0.05) (Fig. 1).  
Table 2 shows comparisons of various biomarkers for coronary risk including the 
EPA/AA and DHA/AA ratios between ACS patients and patients with other disease 
entities, i.e., chronic CAD such as SAP, OMI and CSA, and chest pain syndrome. In 
patients with ACS, the EPA/AA ratio was significantly lower, and the DHA/AA ratio 
tended also to be lower, compared with other patients. Total cholesterol and 
HDL-cholesterol levels were significantly lower and hemoglobin A1c tended to be 
higher in the ACS patients compared with others.  
Multiple logistic regression analysis for discrimination of ACS from other disease 
entities showed that only the EPA/AA ratio (odds ratio: 0.0012, 95% confidence 
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interval: 0.00-0.16, P<0.01), but not DHA/AA ratio (odds ratio: 1.05, 95% confidence 
interval: 0.98-1.12), was a significant independent predictor (Table 3). 
 
 
DISCUSSION 
 
In this study we measured the EPA/AA and DHA/AA ratios in patients with 
definite or suspected CAD. We found that both the EPA/AA ratio and the DHA/AA ratio 
were lower in young patients than in older patients. The EPA/AA ratio was also lower in 
females than in males, but a similar difference was not seen in the DHA/AA ratio. Also, 
the EPA/AA ratio was significantly lower in ACS patients compared with chronic CAD 
or chest pain syndrome patients, while the difference in the DHA/AA ratio was less 
significant. In multivariate analysis, the EPA/AA ratio, but not the DHA/AA ratio, was 
the independent predictor for discriminating ACS from chronic CAD or chest pain 
syndrome. 
It has been shown previously that the EPA/AA ratio is low in young people.8 In 
the present study, the DHA/AA ratio was also lower in younger than in older people. 
This may be a consequence of the westernization of the diet of young Japanese people, 
providing low n-3 PUFA and high n-6 PUFA intakes. PUFA are essential fatty acids, and 
their consumption directly affects their plasma concentration. Also, it has been 
suggested that estrogens affect PUFA metabolism in women, although details are not 
available.9 We have also previously reported the gender difference in EPA/AA ratio.8 
Actually it has been well known that the incidence of hypercholesterolemia is higher in 
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men than women under 40 years old but that this trend reverses as women enter into 
menopause when the level of estrogen production decreases, since estrogen has a known 
mechanism to lower LDL-cholesterol level and raise HDL-cholesterol level. The gender 
difference in the mortality rate from CAD lessens at menopause and disappears when 
they are in the 80’s. It suggests that women’s essential fatty acid metabolism may also 
be affected around the time their sex hormone balances undergo change. The oxidative 
metabolism of estrogen is catalyzed by hepatic cytochrome P450 (CYP450) 
predominantly, and dietary fish oil increases the concentration of CYP450 and some 
subtypes of CYP450 in rat,10 moreover the n-3 PUFA supplementation may decrease the 
metabolism of estradiol.11 Whereas alpha-linolenic acid is converted to subtype of long 
chain n-3 PUFA such as EPA and DHA by desaturase and elongase enzymes in the liver. 
The concentrations of long chain n-3 PUFA may positively associate with circulating 
concentration of estrogen and progesterone, but negatively with testosterone. This may 
suggest sex hormones may act to modify plasma and tissue n-3 PUFA content, possibly 
by altering the expression of desaturase and elongase enzymes. Therefore, the findings 
in the present study that the EPA/AA ratio was lower in female patients than in male 
patients, but that such a gender difference was not seen in the DHA/AA ratio, might be a 
consequence of an effect of sex hormones on PUFA metabolism. 
Although a number of epidemiological studies have found that consumption of 
fish or fish oils prevented early onset of cardiovascular events,12 the mechanism by 
which fish oil might suppress atherogenesis is not understood. Arita et al. 13 
demonstrated that the strong anti-inflammatory and anti-oxidative actions of both EPA 
and DHA metabolites, such as rezolvins and protectins, have the potential to suppress 
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atherogenesis. However, it is not known which metabolites of EPA or DHA are more 
effective for atherosclerosis prevention. On the other hand, the PUFA with 20 carbon 
chain, EPA and AA, which are present in cell membranes, are released by phospholipase 
A and transported into the metabolic cascade. Then they are transformed into 
eicosanoids such as prostaglandins or thromboxanes by cyclooxygenase, or into 
leukotrienes by lipoxygenase, which mediate their biological activities.14-16 The 
AA-derived eicosanoids act as promoters of platelet aggregation and inflammatory cell 
migration, whereas EPA-derived eicosanoids do not do so and are thought to be 
anti-atherosclerotic. However, DHA, which is a PUFA with 22 carbon chain, can never 
be involved in such a metabolic cascade. Therefore, EPA and DHA are potentially 
different in terms of their biological properties. The Japanese JELIS trial demonstrated 
that administration of a high-purity EPA agent reduced the onset of CAD. In particular, 
an inhibitory effect of the EPA agent on the onset of ACS, demonstrated by sub-analysis 
of the JELIS data, merits attention.17 Since ACS is pathologically assumed to be 
characterized by plaque destabilization, plaque rupture and plaque erosion, in which 
inflammation and oxidative stress play a key role,18 anti-inflammatory and 
anti-oxidative properties of the EPA might contribute not a little to its effect on 
inhibiting onset of ACS. Regarding DHA, however, there are no evidence of inhibitory 
effects on ACS onset. Domei et al 19 reported that the risk of developing cardiovascular 
events after percutaneous coronary intervention was increased in association with a low 
EPA/AA ratio, but was independent of the DHA/AA ratio. Lee et al 20 reported that a 
low EPA/AA ratio, but not a low DHA/AA ratio, was predictive of total cardiovascular 
death in patients with ACS. It has also been reported that the concentration of EPA in 
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erythrocytes, but not that of DHA, predicted the incidence of in-hospital death after 
onset of ACS.21 In our present study, the EPA/AA ratio but not the DHA/AA ratio was 
strongly associated with the presence of ACS in patients with CAD, supporting previous 
data. From our results, we can envision that interventions with EPA agents or 
supplemental EPA are likely to confer greater benefit for plaque stabilization to prevent 
ACS in CAD patients, compared with DHA agents or DHA supplements .  
 
Conclusion 
     The EPA/AA ratio might be more closely associated with pathophysiology of 
CAD, especially with that of ACS, compared with the DHA/AA ratio.  
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Figure legends 
 
Figure 1 Comparisons of the EPA/AA and DHA/AA ratios between each 
disease entity of acute coronary syndrome (ACS), stable angina 
pectoris (SAP), old myocardial infarction (OMI), coronary spastic 
angina (CSA), and chest pain syndrome (CPS). The EPA/AA ratio 
was significantly lower in the ACS group compared with each of the 
SAP (P<0.05), CSA (P<0.01) and CPS (P<0.05) groups. The 
DHA/AA ratio in the ACS group was significantly lower than in the 
SAP group. 
 
